PRME - Prime Medicine, Inc. Common Stock

Buy Momentum: Bearish

Recent News

Cathie Wood's Ark Dumps $2.1 Million Of This Hot AI Stock Despite Recent Acquisition Boost - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )

Benzinga • 5 days, 16 hours ago • score: 0.45

On Tuesday, Cathie Wood-led Ark Invest executed a significant trade involving Tempus AI Inc TEM. Ark Invest's decision to sell Tempus AI Inc TEM shares on Tuesday was executed through ARK Genomic Revolution ETF ARKG and ARK Innovation ETF ARKK. ARKG offloaded 6,309 shares, while ARKK sold 19,627 ...

Bullish

PRME Revenue Misses by 73%

Motley Fool • 1 month, 1 week ago • score: 0.22

Prime Medicine ( NASDAQ:PRME ) , a genetic medicine innovator developing next-generation gene editing therapies, released its second quarter 2025 earnings on August 7, 2025. The company reported GAAP revenue of $1.1 million, substantially below analyst estimates of $4.18 million and driven solely ...

Bullish

Prime Medicine, Inc. ( PRME ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.19

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire • 1 month, 1 week ago • score: 0.41

CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of ...

Bullish

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Prime Medicine ( NASDAQ:PRME )

Benzinga • 1 month, 1 week ago • score: 0.39

CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc.

Bullish

Prime Medicine Announces Pricing of Public Offering

GlobeNewswire • 1 month, 2 weeks ago • score: 0.27

CAMBRIDGE, Mass., July 30, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of ...

Bullish

Prime Medicine, Inc. ( PRME ) Now Trades Above Golden Cross: Time to Buy?

Zacks Commentary • 1 month, 2 weeks ago • score: 0.50

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$5.17

52W Low

$1.11

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.40

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.10

EV/Revenue (<3 favorable)

137.30

P/S (TTM) (<3 favorable)

133.68

P/B (<3 favorable)

10.90

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

18.19%

Institutions (25–75% balanced)

44.28%

Shares Outstanding

178,274,000

Float

58,404,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,961,000

Gross Profit (TTM)

-149,456,000

EPS (TTM)

-1.56

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-47.87%

ROE (TTM) (>15% strong)

-1.55%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.46

Momentum

Bearish momentum

Value

0.1287

0.1022

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025